Physician profile

Michael Silpa

Berkeley, CA

NPI 1679684195

$3,108.13

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $684.23 2019-2021
Janssen Biotech, INC. $657.81 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $470.32 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $229.40 2020-2021
Merck Sharp & Dohme LLC $179.97 2019-2021
Ferring Pharmaceuticals INC. $117.49 2020-2021
Pfizer INC. $116.29 2019-2021
Dova Pharmaceuticals $113.18 2019
Daiichi Sankyo INC. $110.37 2020-2021
Janssen Scientific Affairs, LLC $105.09 2019
Intercept Pharmaceuticals, INC. $87.19 2019-2021
Gilead Sciences, INC. $66.81 2020
Concordia Pharmaceuticals INC. $38.60 2019
Allergan, INC. $33.60 2019-2020
Braintree Laboratories, INC. $22.54 2021
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Shionogi INC $19.62 2019
Celgene Corporation $16.48 2021
Amag Pharmaceuticals, INC. $14.57 2020
Lexicon Pharmaceuticals, INC. $12.53 2019
Napo Pharmaceuticals INC $12.04 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Silpa

$3,108.13

in general payments reported 2019-2025

Years
2019-2021
Top company
Abbvie INC.

https://glasscript.com/doctor/75677/michael-silpa

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.